The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 02, 2013

Filed:

Dec. 11, 2008
Applicants:

Albert Collinson, Marlboro, MA (US);

George Avgerinos, Sudbury, MA (US);

Richard Dixon, North Grafton, MA (US);

Tariq Ghayur, Holliston, MA (US);

Zehra Kaymakcalan, Westboro, MA (US);

Inventors:

Albert Collinson, Marlboro, MA (US);

George Avgerinos, Sudbury, MA (US);

Richard Dixon, North Grafton, MA (US);

Tariq Ghayur, Holliston, MA (US);

Zehra Kaymakcalan, Westboro, MA (US);

Assignee:

AbbVie Inc., North Chicago, IL (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 49/00 (2006.01); A61K 39/00 (2006.01); C40B 30/04 (2006.01); C40B 40/10 (2006.01); C40B 50/00 (2006.01); C12N 5/00 (2006.01); C12N 5/02 (2006.01); C12N 15/00 (2006.01); C12N 5/07 (2010.01); C12N 5/16 (2006.01); C12P 21/08 (2006.01);
U.S. Cl.
CPC ...
Abstract

Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1α and IL-1β and neutralize IL-1α and IL-1β activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting two different but structurally related antigens (e.g., IL-1α and IL-1β) and for inhibiting the activity of the antigens, e.g., in a human subject suffering from a disorder in which IL-1α and/or IL-1β activity is detrimental.


Find Patent Forward Citations

Loading…